2.68
price down icon2.90%   -0.08
after-market After Hours: 2.73 0.05 +1.87%
loading
Fate Therapeutics Inc stock is traded at $2.68, with a volume of 1.28M. It is down -2.90% in the last 24 hours and down -16.77% over the past month. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$2.76
Open:
$2.81
24h Volume:
1.28M
Relative Volume:
1.05
Market Cap:
$305.19M
Revenue:
$12.32M
Net Income/Loss:
$-175.72M
P/E Ratio:
-1.235
EPS:
-2.17
Net Cash Flow:
$-141.45M
1W Performance:
-1.47%
1M Performance:
-16.77%
6M Performance:
-33.99%
1Y Performance:
+12.13%
1-Day Range:
Value
$2.495
$2.81
1-Week Range:
Value
$2.27
$2.81
52-Week Range:
Value
$1.91
$8.83

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
Name
Fate Therapeutics Inc
Name
Phone
858.875.1803
Name
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
Employee
181
Name
Twitter
@fatethx
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
FATE's Discussions on Twitter

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-17-24 Upgrade Piper Sandler Neutral → Overweight
Mar-27-23 Resumed Wells Fargo Equal Weight
Jan-24-23 Downgrade H.C. Wainwright Buy → Neutral
Jan-06-23 Downgrade BMO Capital Markets Outperform → Market Perform
Jan-06-23 Downgrade BofA Securities Buy → Underperform
Jan-06-23 Downgrade Cowen Outperform → Market Perform
Jan-06-23 Downgrade Piper Sandler Overweight → Neutral
Jan-06-23 Downgrade Stifel Buy → Hold
Jan-06-23 Downgrade Truist Buy → Hold
Jan-06-23 Downgrade Wedbush Outperform → Neutral
Jan-03-23 Downgrade Guggenheim Buy → Neutral
Dec-22-22 Downgrade Oppenheimer Outperform → Perform
Dec-15-22 Initiated Goldman Sell
Nov-04-22 Resumed Cantor Fitzgerald Overweight
Oct-10-22 Initiated Canaccord Genuity Buy
Aug-18-22 Resumed Wells Fargo Overweight
Jul-28-22 Initiated Needham Hold
Jul-11-22 Upgrade BMO Capital Markets Market Perform → Outperform
Jun-03-22 Initiated Robert W. Baird Neutral
Feb-11-22 Resumed BMO Capital Markets Market Perform
Dec-15-21 Upgrade Wedbush Neutral → Outperform
Dec-07-21 Initiated Cowen Outperform
Nov-09-21 Upgrade Citigroup Neutral → Buy
Aug-26-21 Initiated Morgan Stanley Equal-Weight
Jun-07-21 Upgrade H.C. Wainwright Neutral → Buy
May-07-21 Upgrade Wedbush Neutral → Outperform
Apr-26-21 Resumed Jefferies Buy
Feb-26-21 Initiated BofA Securities Buy
Feb-26-21 Downgrade Wedbush Outperform → Neutral
Feb-11-21 Downgrade Citigroup Buy → Neutral
Jan-27-21 Resumed H.C. Wainwright Neutral
May-13-20 Initiated H.C. Wainwright Buy
Mar-04-20 Initiated Barclays Overweight
Jan-09-20 Downgrade BMO Capital Markets Outperform → Market Perform
Dec-30-19 Reiterated Mizuho Buy
Dec-09-19 Upgrade Wells Fargo Market Perform → Outperform
Nov-12-19 Initiated SunTrust Buy
Nov-06-19 Downgrade Wells Fargo Outperform → Market Perform
Oct-01-19 Initiated Stifel Buy
Aug-09-19 Initiated BTIG Research Buy
Jul-22-19 Initiated Cantor Fitzgerald Overweight
Jul-12-19 Initiated Oppenheimer Outperform
Jun-13-19 Initiated Mizuho Buy
Jun-07-19 Initiated ROTH Capital Neutral
May-31-19 Initiated Guggenheim Buy
May-24-19 Resumed Citigroup Buy
Mar-28-19 Initiated SVB Leerink Outperform
Jan-03-19 Downgrade Stephens Overweight → Equal-Weight
Nov-05-18 Initiated Jefferies Buy
Aug-01-18 Initiated Citigroup Buy
Mar-06-18 Downgrade H.C. Wainwright Buy → Neutral
View All

Fate Therapeutics Inc Stock (FATE) Latest News

pulisher
Nov 04, 2024

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 04, 2024
pulisher
Oct 25, 2024

Fate Therapeutics Drops To US$2.81, Yet Insiders May Have Sold Too Early - Simply Wall St

Oct 25, 2024
pulisher
Oct 22, 2024

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionFATE - AsiaOne

Oct 22, 2024
pulisher
Oct 17, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World

Oct 17, 2024
pulisher
Oct 16, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 5.7% in September - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Fate Therapeutics Inc (FATE) looking to reclaim success with recent performance - SETE News

Oct 16, 2024
pulisher
Oct 15, 2024

Was Fate Therapeutics Inc (FATE)’s session last reading good? - US Post News

Oct 15, 2024
pulisher
Oct 14, 2024

Market Recap Check: Fate Therapeutics Inc (FATE)’s Positive Finish at 3.09, Up/Down 5.10 - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of "Hold" from Analysts - MarketBeat

Oct 14, 2024
pulisher
Oct 09, 2024

Fate Therapeutics Inc [FATE] stock was sold by Xu Yuan at the price of US$2678.0 - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

Dimensional Fund Advisors LP Has $6.99 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Oct 09, 2024
pulisher
Oct 08, 2024

Holdings of Fate Therapeutics Inc (FATE) are aligned with the stars - SETE News

Oct 08, 2024
pulisher
Oct 08, 2024

Fate Therapeutics Inc (FATE) Stock: Heads Or Tails? - Stocks Register

Oct 08, 2024
pulisher
Oct 07, 2024

The Fate Therapeutics Inc (FATE) Stock Is Headed for a Correction - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Market Insight: Fate Therapeutics Inc (FATE)’s Notable Gain, Closing at 3.22 - The Dwinnex

Oct 07, 2024
pulisher
Oct 04, 2024

Renaissance Technologies LLC Takes Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

Fate Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle

Oct 03, 2024
pulisher
Oct 02, 2024

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 02, 2024
pulisher
Oct 01, 2024

Can you still get a good price for Fate Therapeutics Inc (FATE) Shares at this point? - US Post News

Oct 01, 2024
pulisher
Sep 30, 2024

Fate Therapeutics' SWOT analysis: cell therapy stock poised for pivotal year - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Investor’s Toolkit: Key Ratios for Assessing Fate Therapeutics Inc (FATE)’s Performance - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

Perceptive Advisors LLC Purchases New Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

You might want to take a look at Fate Therapeutics Inc (FATE) now - SETE News

Sep 30, 2024
pulisher
Sep 26, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Holdings Lifted by Deerfield Management Company L.P. Series C - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

FATE’s Debt-to-Equity Ratio at 0.25: What It Means for Fate Therapeutics Inc’s Future - The InvestChronicle

Sep 25, 2024
pulisher
Sep 24, 2024

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bumble Inc. - GlobeNewswire

Sep 24, 2024
pulisher
Sep 24, 2024

Fate Trigger The Novita Cinematic Teaser - GameSpot

Sep 24, 2024
pulisher
Sep 24, 2024

FTR: Trailer orders remain below expectations - Fleet Equipment Magazine

Sep 24, 2024
pulisher
Sep 24, 2024

Should investors be concerned about Fate Therapeutics Inc (FATE)? - US Post News

Sep 24, 2024
pulisher
Sep 23, 2024

FendX Provides Corporate Update - Newsfile

Sep 23, 2024
pulisher
Sep 23, 2024

Closing Figures: Fate Therapeutics Inc (FATE)’s Negative Finish at 3.87, Down -3.25 - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Integral Health Asset Management LLC Acquires 650,000 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Sep 23, 2024
pulisher
Sep 21, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Acquired by Bank of New York Mellon Corp - Defense World

Sep 21, 2024
pulisher
Sep 19, 2024

FTR reports August 2024 trailer orders were below projections - Trucks, Parts, Service

Sep 19, 2024
pulisher
Sep 19, 2024

Kaskela Law LLC Announces Shareholder Investigation of Fate - GlobeNewswire

Sep 19, 2024
pulisher
Sep 19, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $6.90 Consensus Price Target from Brokerages - MarketBeat

Sep 19, 2024
pulisher
Sep 18, 2024

Top investors say Fate Therapeutics Inc (FATE) ticks everything they need - SETE News

Sep 18, 2024
pulisher
Sep 18, 2024

E Fund Management Co. Ltd. Increases Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Sep 18, 2024
pulisher
Sep 17, 2024

Technical analysis of Fate Therapeutics Inc (FATE) stock chart patterns - US Post News

Sep 17, 2024
pulisher
Sep 16, 2024

Bruce & Co. Inc. Has $984,000 Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Sep 16, 2024
pulisher
Sep 12, 2024

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference - GlobeNewswire

Sep 12, 2024
pulisher
Sep 12, 2024

Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? - Yahoo Finance

Sep 12, 2024
pulisher
Sep 12, 2024

Acadian Asset Management LLC Increases Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Sep 12, 2024
pulisher
Sep 12, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Stake Lifted by Acadian Asset Management LLC - Defense World

Sep 12, 2024
pulisher
Sep 10, 2024

Are Smart Investors Making the Right Decision? Fate Therapeutics Inc (FATE) - SETE News

Sep 10, 2024
pulisher
Sep 09, 2024

Examining Fate Therapeutics Inc (FATE) more closely is necessary - US Post News

Sep 09, 2024
pulisher
Sep 09, 2024

Financial Analysis: Fate Therapeutics Inc (FATE)’s Ratios Unveil Key Insights - The Dwinnex

Sep 09, 2024
pulisher
Sep 05, 2024

There is no way Fate Therapeutics Inc (FATE) can keep these numbers up - SETE News

Sep 05, 2024
pulisher
Sep 04, 2024

FATE underperforms with a -5.99 decrease in share price - US Post News

Sep 04, 2024
pulisher
Sep 03, 2024

Deeper Dive: Understanding Fate Therapeutics Inc (FATE) Through its Various Ratios - The Dwinnex

Sep 03, 2024
pulisher
Sep 03, 2024

Bone Degeneration Therapeutics Market Outlook, Growth By Top - openPR

Sep 03, 2024

Fate Therapeutics Inc Stock (FATE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):